Mankind Pharma (NSE:MANKIND) announced on 20 August 2026 that it has entered an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd., China, to commercialise two insulin analogues, Insulin Degludec and Insulin Degludec plus Aspart Combination, in India.
Key Highlights
- Mankind Pharma has signed an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd. of China for two insulin analogue products.
- The licensed products are Insulin Degludec and Insulin Degludec plus Aspart Combination, both targeted at the injectable diabetes therapy segment in India.
- The agreement extends Mankind Pharma's existing in-licensing relationship with Chinese biopharmaceutical partners, which previously included Insulin Aspart.
- Mankind Pharma operates a field force of over 18,500 professionals with a reach extending to more than five lakh doctors across India, supporting commercialisation.
About the Company
Mankind Pharma Limited (NSE:MANKIND, BSE:543904) is headquartered in New Delhi and is one of India's largest pharmaceutical companies focused on the domestic market. The company operates across acute and chronic therapeutic areas including antidiabetic, cardiovascular, anti-infectives, and respiratory segments, and in consumer healthcare through brands in contraceptives, antacids, and vitamin supplements. It has 32 manufacturing facilities and seven dedicated R&D centres staffed by more than 740 scientists across India.
Announcement in Detail
Through the 20 August 2026 exchange filing, Mankind Pharma disclosed that it has entered into an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd. of China for the commercialisation of Insulin Degludec and Insulin Degludec plus Aspart Combination in India. No financial consideration or deal value was disclosed in the announcement.
Commenting on the agreement, Atish Majumdar, Senior President, Sales and Marketing at Mankind Pharma, noted that China is emerging as a hub for innovative biopharmaceutical assets and that this partnership builds on prior agreements for Insulin Aspart and Insulin Degludec. The company stated its intent to continue expanding its in-licensing pipeline from China to broaden access to advanced therapies for patients in India.
Impact on Investors
The filing shows that this agreement adds two insulin analogue products to Mankind Pharma's injectable diabetes portfolio under an exclusive arrangement, meaning no other company can market these specific licensed products in India on the counterparty's behalf. Investors will note that the announcement does not disclose the financial terms, royalty structure, milestone payments, or revenue projections associated with this agreement, so the direct earnings contribution cannot be assessed from the disclosed information alone.
Shareholders will observe that the deal aligns with the company's stated strategy of expanding its chronic therapy presence, particularly in the antidiabetic segment. The company's existing distribution infrastructure, covering over five lakh doctors, provides a commercialisation base for any new injectable products brought to market under such agreements.
Sector / Market Context
India has one of the largest diabetic populations globally, with the International Diabetes Federation estimating over 100 million people living with diabetes in the country. The injectable insulin segment, including long-acting analogues such as Insulin Degludec, represents a growing sub-category as treatment protocols shift toward more advanced formulations. Indian pharmaceutical companies have increasingly pursued in-licensing arrangements with Chinese biopharmaceutical firms to access differentiated biological assets for the domestic market.